MothaffarF.RimawiMD

Oncology • Houston, TX

Breast Cancer

Professor and Executive Medical Director, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine

Join to view full profile

Dr. Rimawi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Rimawi's full profile

Already have an account?

Office
Dan L Duncan Comprehensive Cancer Center
7200 Cambridge St. 7A
Houston, TX 77030
Phone+1 713-798-1999

Fax+1 713-798-1910
Is this information wrong?

Education & Training

Baylor College of MedicineBreast Oncology, 2003 - 2005
Baylor College of MedicineFellowship, Hematology and Medical Oncology, 2001 - 2004
Baylor College of MedicineResidency, Internal Medicine, 1998 - 2001
University of Jordan Faculty of MedicineClass of 1997

Certifications & Licensure

IN State Medical License 2004 - 2025
TX State Medical License 2005 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Top Doctors:SE Texas Castle Connolly, 2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Neoadjuvant Herceptin in Patients With Breast Cancer Start of enrollment: 2001 Oct 01
Terminated
Phase 2
Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer Start of enrollment: 2003 Jan 01
Terminated
Phase 2
Neoadjuvant GW572016 to Treat Breast Cancer Start of enrollment: 2004 Aug 01
Completed
Phase 2
Nexium Study To Suppress Nausea During Chemotherapy Start of enrollment: 2005 Aug 01
Terminated
Phase 3
Extension Neoadjuvant Taxotere: Study of the Effects of Taxotere in Patients With Breast Cancer Start of enrollment: 2002 Jan 01
Terminated
Phase 2
Biologic Correlative Taxotere/AC Start of enrollment: 2002 Apr 01
Completed
Phase 2
Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients Start of enrollment: 2004 Sep 01
Completed
Phase 2
Lapatinib and Trastuzumab With or Without Endocrine Therapy Start of enrollment: 2008 May 01
Completed
Phase 2
Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer Start of enrollment: 2007 Dec 01
Completed
Phase 2
Brain Mets - Capecitabine Plus Sunitinib and WBRT Start of enrollment: 2009 Feb 01
Terminated
Phase 2
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients Start of enrollment: 2008 Dec 01
Terminated
Phase 2
Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy Start of enrollment: 2011 Oct 01
Active, not recruiting
Phase 2
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer Start of enrollment: 2012 Aug 01
Completed
Phase 2
Scalp Cooling to Prevent Chemo-induced Hair Loss Start of enrollment: 2014 May 15
Active, not recruiting
Not Applicable
High Dose Vitamin D vs Standard Dose Vitamin D Study Start of enrollment: 2013 Dec 01
Terminated
Phase 2
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Start of enrollment: 2014 Jan 15
Active, not recruiting
Phase 3
CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer Start of enrollment: 2014 Jun 01
Terminated
Phase 1
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Start of enrollment: 2014 Jul 22
Active, not recruiting
Phase 3
Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer Start of enrollment: 2015 Jun 01
Terminated
Phase 1, Phase 2
TACTIC - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer Start of enrollment: 2017 Oct 10
Active, not recruiting
Phase 2
ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer Start of enrollment: 2019 May 25
Active, not recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or...
Cynthia X Ma, Vera J Suman, Souzan Sanati, Kiran Vij, Meenakshi Anurag, A Marilyn Leitch, Gary W Unzeitig, Jeremy Hoog, Aranzazu Fernandez-Martinez, Cheng Fan, Richard...> ;JAMA Oncology. 2024 Mar 1
5 citations
Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors.
Xiangdong Lv, Xuan Lu, Jin Cao, Qin Luo, Yao Ding, Fanglue Peng, Apar Pataer, Dong Lu, Dong Han, Eric Malmberg, Doug W Chan, Xiaoran Wang, Sara R Savage, Sufeng Mao, J...> ;Science. 2023 Sep 8
3 citations
Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial).
Maeve A Hennessy, Jeffrey P Leal, Chiung-Yu Huang, Lilja B Solnes, Rita Denbow, Vandana G Abramson, Lisa A Carey, Minetta C Liu, Mothaffar Rimawi, Jennifer Specht, Ann...> ;Journal of Nuclear Medicine. 2023 Nov 1
Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins.
Junkai Wang, Alexander B Saltzman, Eric J Jaehnig, Jonathan T Lei, Anna Malovannaya, Matthew V Holt, Meggie N Young, Mothaffar F Rimawi, Foluso O Ademuyiwa, Meenakshi ...> ;Cancer Research Communications. 2023 Aug 1
High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer.
Xiaoyong Fu, Resel Pereira, Chia-Chia Liu, Carmine De Angelis, Martin J Shea, Sarmistha Nanda, Lanfang Qin, Tamika Mitchell, Maria L Cataldo, Jamunarani Veeraraghavan,...> ;Cell Reports. 2023 Aug 29
6 citations
Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2-...
Hope S Rugo, Christine L Crossno, Yaron B Gesthalter, Kristen Kelley, Heather B Moore, Mothaffar F Rimawi, Kelly E Westbrook, Saundra S Buys> ;JCO Oncology Practice. 2023 Aug 1
2 citations
A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer.
Jamunarani Veeraraghavan, Carolina Gutierrez, Carmine De Angelis, Robert Davis, Tao Wang, Tomas Pascual, Pier Selenica, Katherine Sanchez, Hiroaki Nitta, Monesh Kapadi...> ;Clinical Cancer Research. 2023 Aug 15
2 citations
Margetuximab in HER2-positive metastatic breast cancer.
William J Gradishar, Ruth O'Regan, Mothaffar F Rimawi, Jeffrey L Nordstrom, Minori K Rosales, Hope S Rugo> ;Future Oncology. 2023 May 1
1 citations
Toward Practical Integration of Omic and Imaging Data in Co-Clinical Trials.
Emel Alkim, Heidi Dowst, Julie DiCarlo, Lacey E Dobrolecki, Anadulce Hernández-Herrera, David A Hormuth 2nd, Yuxing Liao, Apollo McOwiti, Robia Pautler, Mothaffar Rima...> ;Tomography. 2023 Apr 10
3 citations
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030.
Heather A Parsons, Timothy Blewett, Xiangying Chu, Sainetra Sridhar, Katheryn Santos, Kan Xiong, Vandana G Abramson, Ashka Patel, Ju Cheng, Adam Brufsky, Justin Rhoade...> ;Medrxiv. 2023 Mar 8
6 citations
Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis.
Grazia Arpino, Juan de la Haba Rodríguez, Jean-Marc Ferrero, Sabino De Placido, C Kent Osborne, Dirk Klingbiel, Valentine Revelant, Christine Wohlfarth, Raf Poppe, Mot...> ;Clinical Cancer Research. 2023 Apr 14
11 citations
Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approach.
Varduhi Petrosyan, Lacey E Dobrolecki, Lillian Thistlethwaite, Alaina N Lewis, Christina Sallas, Ramakrishnan R Srinivasan, Jonathan T Lei, Vladimir Kovacevic, Predrag...> ;Iscience. 2023 Jan 20
26 citations
Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis.
Susana Garcia-Recio, Toshinori Hinoue, Gregory L Wheeler, Benjamin J Kelly, Ana C Garrido-Castro, Tomas Pascual, Aguirre A De Cubas, Youli Xia, Brooke M Felsheim, Marn...> ;Nature Cancer. 2023 Jan 1
1 citations
The Aetion Coalition to Advance Real-World Evidence through Randomized Controlled Trial Emulation Initiative: Oncology.
David Merola, Ulka Campbell, Nileesa Gautam, Alexa Rubens, Sebastian Schneeweiss, Shirley V Wang, Gillis Carrigan, Victoria Chia, Osayi E Ovbiosa, Simone Pinheiro, Ama...> ;Clinical Pharmacology and Therapeutics. 2023 Jun 1
18 citations
Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer.
Meenakshi Anurag, Eric J Jaehnig, Karsten Krug, Jonathan T Lei, Erik J Bergstrom, Beom-Jun Kim, Tanmayi D Vashist, Anh Minh Tran Huynh, Yongchao Dou, Xuxu Gou, Chen Hu...> ;Cancer Discovery. 2022 Nov 2
7 citations
Elacestrant and the Promise of Oral SERDs.
Katherine G Sanchez, Julie R Nangia, Rachel Schiff, Mothaffar F Rimawi> ;Journal of Clinical Oncology. 2022 Oct 1
8 citations
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TB...
Romualdo Barroso-Sousa, Paolo Tarantino, Nabihah Tayob, Chau Dang, Denise A Yardley, Steven J Isakoff, Vicente Valero, Meredith Faggen, Therese Mulvey, Ron Bose, Jiani...> ;NPJ Breast Cancer. 2022 Feb 16
6 citations
Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer.
Valentina Hoyos, Spyridoula Vasileiou, Manik Kuvalekar, Ayumi Watanabe, Ifigeneia Tzannou, Yovana Velazquez, Matthew French-Kim, Wingchi Leung, Suhasini Lulla, Catheri...> ;Therapeutic Advances in Medical Oncology. 2022 Jan 1
7 citations
Biomarkers of response and resistance to palbociclib plus letrozole in patients with ER+/HER2- breast cancer.
Mitch Dowsett, Lucy Kilburn, Mothaffar F. Rimawi, C. Kent Osborne, Katherine L. Pogue-Geile, Yuan Liu, Samuel A. Jacobs, Melanie Finnigan, Shannon Puhalla, Andrew Dods...> ;Clinical Cancer Research. 2021 Oct 13
1 citations
Breast Cancer Prevention: Where Are We?
Julie R. Nangia, Mothaffar F. Rimawi> ;JCO Oncology Practice. 2021 Oct 7
7 citations
Management of hormone receptor–positive, human epidermal growth factor 2–negative metastatic breast cancer
Jason A. Mouabbi, C. Kent Osborne, Rachel Schiff, Mothaffar F. Rimawi> ;Breast Cancer Research and Treatment. 2021 Sep 13
1 citations
Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer.
Carmine De Angelis, Xiaoyong Fu, Maria Letizia Cataldo, Agostina Nardone, Resel Pereira, Jamunarani Veeraraghavan, Sarmistha Nanda, Lanfang Qin, Vidyalakshmi Sethunath...> ;Clinical Cancer Research. 2021 Sep 1
21 citations
Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer
Foluso O. Ademuyiwa, Ina Chen, Jingqin Luo, Mothaffar F. Rimawi, Ian S. Hagemann, Bryan Fisk, Gejae Jeffers, Zachary L. Skidmore, Anamika Basu, Megan Richters, Cynthia...> ;Breast Cancer Research and Treatment. 2021 Jun 26
14 citations
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Tr...
Kathryn J. Ruddy, Yue Zheng, Nabihah Tayob, Jiani Hu, Chau T. Dang, Denise A. Yardley, Steven J. Isakoff, Vicente Valero, Meredith Faggen, Therese M. Mulvey, Ron Bose,...> ;Breast Cancer Research and Treatment. 2021 Jun 12
5 citations
Lumpectomy followed by radiation improves survival in HER2 positive and triple-negative breast cancer with high tumor-infiltrating lymphocytes compared to mastectomy a...
Jason A Mouabbi, Momal Chand, Ishaq A. Asghar, Ramen Sakhi, Daniel Ockner, Carrie L. Dul, Tarik Hadid, Amr Aref, Mothaffar F. Rimawi, Valentina Hoyos> ;Cancer Medicine. 2021 Jun 3
Join now to see all

Journal Articles

The Oral Selective Oestrogen Receptor Degrader (SERD) AZD9496 Is Comparable to Fulvestrant in Antagonising ER and Circumventing Endocrine Resistance
Rinath Jeselsohn, Mothaffar F Rimawi, C Kent Osborne, Rachel Schiff, Nature

Lectures

Advances in HER2-Positive Breast Cancer
2012 International Symposium, San Antonio, Texas, USA
Advances in HER2-Positive Breast Cancer
San Antonio Breast Cancer Symposium, 2012 International Symposium, San Antonio, Texas, USA

Press Mentions

Greenwich LifeSciences Provides Year End UpdateDecember 29th, 2022
$NCI/NIH Award $2 Million to Immunicom to Initiate Clinical Trial Evaluating Breakthrough Immunopheresis® LW-02 Molecular Subtractive Therapy in Refractory ER+/Her2- Breast Cancer$
NCI/NIH Award $2 Million to Immunicom to Initiate Clinical Trial Evaluating Breakthrough Immunopheresis® LW-02 Molecular Subtractive Therapy in Refractory ER+/Her2- Breast CancerJune 14th, 2022
Long-Term Repercussions of Postponing Care Due to COVID-19March 8th, 2021
Join now to see all